Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.

Cohen, Jordana B

Hanff, Thomas C

Corrales-Medina, Vicente

William, Preethi

Renna, Nicolas

Rosado-Santander, Nelson R

Rodriguez-Mori, Juan E

Spaak, Jonas

Andrade-Villanueva, Jaime

Chang, Tara I

Barbagelata, Alejandro

Alfonso, Carlos E

Bernales-Salas, Eduardo

Coacalla, Johanna

Castro-Callirgos, Carlos Augusto

Tupayachi-Venero, Karen E

Medina, Carola

Valdivia, Renzo

Villavicencio, Mirko

Vasquez, Charles R

Harhay, Michael O

Chittams, Jesse

Sharkoski, Tiffany

Byrd, James Brian

Edmonston, Daniel L

Sweitzer, Nancy

Chirinos, Julio A

2024-04-02T01:23:21Z

2024-04-02T01:23:21Z

2020-10

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), is associated with high incidence of multiorgan dysfunction and death. Angiotensin-converting enzyme 2 (ACE2), which facilitates SARS-CoV-2 host cell entry, may be impacted by angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), two commonly used antihypertensive classes. In a multicenter, international randomized controlled trial that began enrollment on March 31, 2020, participants are randomized to continuation vs withdrawal of their long-term outpatient ACEI or ARB upon hospitalization with COVID-19. The primary outcome is a hierarchical global rank score incorporating time to death, duration of mechanical ventilation, duration of renal replacement or vasopressor therapy, and multiorgan dysfunction severity. Approval for the study has been obtained from the Institutional Review Board of each participating institution, and all participants will provide informed consent. A data safety monitoring board has been assembled to provide independent oversight of the project.

1524-6175

1751-7176

https://hdl.handle.net/10161/30459

eng

Wiley

Journal of clinical hypertension (Greenwich, Conn.)

10.1111/jch.14011

https://creativecommons.org/licenses/by-nc/4.0

Humans

Multiple Organ Failure

Vasoconstrictor Agents

Angiotensin-Converting Enzyme Inhibitors

Respiration, Artificial

Hospitalization

Withholding Treatment

Renal Replacement Therapy

Severity of Illness Index

Incidence

Case-Control Studies

Prospective Studies

Adult

Female

Male

Angiotensin Receptor Antagonists

COVID-19

SARS-CoV-2

Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.

Journal article

Barbagelata, Alejandro|0000-0001-6803-2605

Edmonston, Daniel L|0000-0003-2589-6993

1780

1788

10

Duke

School of Medicine

Clinical Science Departments

Medicine

Medicine, Cardiology

Medicine, Nephrology

Published

22